Astellas is committed to providing timely and accurate information about our business, science and products. This section offers global resources for investors, journalists and media professionals. News and resources from our local affiliates can be viewed in the Local news section. If you are not an investor or journalist, click here.
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Japan, November 29, 2005 - Astellas Pharma Inc. ("Astellas"; headquarters: Tokyo; President and CEO: Toichi Takenaka) today announced that Astellas filed a patent infringement lawsuit on November...
Japan, October 21, 2005 - Astellas Pharma Inc. (Head Office: Tokyo, President & CEO: Toichi Takenaka, hereafter referred as "Astellas") today announced that the fast-disintegrating tablet technology "
Japan, October 12, 2005 - Astellas Pharma Inc. (Head Office: Tokyo, President & CEO: Toichi Takenaka, hereafter referred as "Astellas") today announced that the antidepressant "Luvox® Tablet"...
Read more about Luvox® Receives Approval for Social Anxiety Disorder as an Additional Indication
Japan, October 12, 2005 - Astellas Pharma Inc. (Head Office: Tokyo, President & CEO: Toichi Takenaka, hereafter referred as "Astellas") today announced that Astellas will make a donation of...
Astellas Pharma Inc. ("Astellas"; headquarters: Tokyo; President and CEO: Toichi Takenaka) filed a patent infringement lawsuit on September 15 with the Tokyo District court against Taiyo Yakuhin...
Japan, September 5, 2005 - Astellas Pharma Inc. (Head Office: Tokyo, President & CEO: Toichi Takenaka, hereafter referred as "Astellas") today announced that the Astellas Group will make a...
Read more about Astellas to Support the Relief Effort Following Hurricane Katrina Hit in the US
Japan, July 6, 2005 - Astellas Pharma Inc. today announced that Astellas US LLC, its wholly owned subsidiary headquartered in Deerfield, IL.(Chairman and CEO; Makoto Nishimura, Ph.D.) has executed...
Read more about Astellas has ended the agreement regarding "AczoneTM" in North America
Astellas Pharma Inc. ("Astellas"; headquarters: Tokyo; President and CEO: Toichi Takenaka) decided at a board meeting held on June 24 to integrate its active pharmaceutical ingredient (API)...
Read more about Separation of the API Production at Takahagi Site
Japan, June 10, 2005 - Astellas Pharma Inc. ("Astellas") today announced that a new dosage form of Harnal® (generic name: tamsulosin HCl), the orally disintegrating tablet "Harnal® D Tablet...
Follow us
